<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations/><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/9723A08C-7FA8-46D9-A673-FF519D47EF4C"><gtr:id>9723A08C-7FA8-46D9-A673-FF519D47EF4C</gtr:id><gtr:name>Bioxydyn Limited</gtr:name><gtr:address><gtr:line1>RUTHERFORD HOUSE , PENCROFT WAY</gtr:line1><gtr:city>MANCHESTER</gtr:city><gtr:postCode>M15 6SZ</gtr:postCode><gtr:region>North West</gtr:region></gtr:address><gtr:typeInd>P</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/9723A08C-7FA8-46D9-A673-FF519D47EF4C" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="gtr:organisationParticipantRole"><gtr:id>9723A08C-7FA8-46D9-A673-FF519D47EF4C</gtr:id><gtr:name>Bioxydyn Limited</gtr:name><gtr:address><gtr:line1>RUTHERFORD HOUSE , PENCROFT WAY</gtr:line1><gtr:city>MANCHESTER</gtr:city><gtr:postCode>M15 6SZ</gtr:postCode><gtr:region>North West</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_PARTICIPANT</gtr:name></gtr:role><gtr:role><gtr:name>PARTICIPANT</gtr:name></gtr:role></gtr:roles><gtr:offerGrant>249989.0</gtr:offerGrant><gtr:projectCost>739395.0</gtr:projectCost></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/C3B4B3DB-4471-4942-AD58-A9844AE397B7"><gtr:id>C3B4B3DB-4471-4942-AD58-A9844AE397B7</gtr:id><gtr:firstName>Derek</gtr:firstName><gtr:surname>Bannister</gtr:surname><gtr:roles><gtr:role><gtr:name>PROJECT_MANAGER</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=720319"><gtr:id>9C46A6B1-686F-4A2D-8098-BF40672AD936</gtr:id><gtr:title>3D functional oxygen-enhanced lung imaging</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>GRD Development of Prototype</gtr:grantCategory><gtr:grantReference>720319</gtr:grantReference><gtr:abstractText>Chronic obstructive pulmonary disease (COPD) is a chronic respiratory disease, characterized by airflow obstruction to the lungs, interfering with normal breathing. It is one of the most common respiratory diseases and the WHO predicts it to be the 3rd leading cause of death worldwide by 2020.
Early clinical diagnosis is critical to prevent further deterioration of the lungs and improved patient care. However, there is no single diagnostic test for COPD and current clinical diagnostic and lung imaging techniques rely upon diagnostic tests that are non-specific, unreliable, time consuming, or that use harmful radiation, restricting their repeated use in patients for monitoring disease progression or therapeutic response. Bioxydyn Limited are an SME founded in 2009, with the objective of developing a software tool with associated gas delivery and scanning protocols for functional lung imaging using Oxygen Enhanced Magnetic Resonance Imaging (OE-MRI). Their technique is novel and will revolutionise the use of imaging in COPD and other forms of lung disease. It will provide a safe, non-invasive regionally-resolved approach to measure lung function and anatomy that can be used to assess disease status and treatment response.
This project will result in a 3D OE-MRI scanning protocol for use in radiology settings in
hospitals worldwide, communicating with MRI systems via Picture Archiving &amp;amp;
Communication Systems (PACS) &amp;amp; with other hospital information systems. Initial market
entry with a beta release package is anticipated early 2015.</gtr:abstractText><gtr:fund><gtr:end>2014-12-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/E18E2F0F-AC7D-4E02-9559-669F7C8FEC74"><gtr:id>E18E2F0F-AC7D-4E02-9559-669F7C8FEC74</gtr:id><gtr:name>Innovate UK</gtr:name></gtr:funder><gtr:start>2013-06-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>249989</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs/><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications/><gtr:identifiers><gtr:identifier type="RCUK">720319</gtr:identifier></gtr:identifiers><gtr:healthCategories/><gtr:researchActivities/><gtr:researchSubjects/><gtr:researchTopics><gtr:researchTopic><gtr:id>D05BC2E0-0345-4A3F-8C3F-775BC42A0819</gtr:id><gtr:text>Unclassified</gtr:text></gtr:researchTopic></gtr:researchTopics><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>